Abstract
During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Keywords: Multidrug resistance, P-gp inhibitor, development
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in the Development of P-gp Inhibitors
Volume: 9 Issue: 4
Author(s): Christiane Baumert and Andreas Hilgeroth
Affiliation:
Keywords: Multidrug resistance, P-gp inhibitor, development
Abstract: During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Export Options
About this article
Cite this article as:
Baumert Christiane and Hilgeroth Andreas, Recent Advances in the Development of P-gp Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040415
DOI https://dx.doi.org/10.2174/1871520610909040415 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science Fine-tuning of microRNAs in Type 2 Diabetes Mellitus
Current Medicinal Chemistry Subject Index to Volume 2
Current Pharmacogenomics Evaluation of the in vitro Antitumor Activity of Nanostructured Cyclotides in Polymers of Eudragit® L 100-55 and RS 30 D
Letters in Drug Design & Discovery Lectins as Ligands for Directing Nanostructured Systems
Current Drug Delivery Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry Graphical Abstracts
Current Drug Delivery Histone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy
Current Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy EDITORIAL(Hot Topic Integrated Therapeutic Approaches in the Treatment of Human Cancer)
Anti-Cancer Agents in Medicinal Chemistry Ulipristal Acetate (Esmya) in the Management of Heavy Menstrual Bleeding Associated with Fibroids: A Case Series
Current Women`s Health Reviews Bioactive Food Components as Dietary Intervention for Cystic Fibrosis
Current Drug Targets Chemistry, Stability and Bioavailability of Resveratrol
Medicinal Chemistry Drug Repurposing: Translational Pharmacology, Chemistry, Computers and the Clinic
Current Topics in Medicinal Chemistry Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery